GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04102189

CompletedPhase 3Results posted

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

201

actual

Study population

Obesity / overweight

Key I/E criteria

•HbA1c ≤10%•Age 12-17

Primary endpoint

•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04102189

Org study IDNN9536-4451

Secondary ID2018-002431-18

Secondary IDU1111-1215-7560World Health Organization (WHO)

Timeline

Milestones

Study first posted2019-09-25actual

Study start2019-10-07actual

Primary completion2022-03-25actual

Study completion2022-03-28actual

Results first posted2023-04-18actual

Last update posted2025-12-11actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age12 Years

Maximum age17 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent of parent(s) or legally acceptable representative of subject and child assent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial

•Male or female, ages 12 to below 18 years at the time of signing informed consent

•BMI equal to or above 95th percentile OR equal to or above 85th percentile (on gender and age-specific growth charts (CDC.gov)) with 1 or more weight related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes

•History of at least one self-reported unsuccessful dietary effort to lose weight

For subjects with type 2 diabetes at screening the following inclusion criteria apply in addition:

- HbA1c equal to or below 10.0% (86 mmol/mol) as measured by central laboratory at screening

Exclusion criteria

•Prepubertal subjects (Tanner stage 1)

•History of type 1 diabetes

•A self-reported (or by parent(s)/legally acceptable representative where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records

•Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)

•For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Endpoints (76)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Glycemic / diabetes

Safety / tolerability / PK

MASH / liver

Weight & body composition

26 endpoints

Primary/registry result

Change in Body Mass Index (BMI) (Percentage [%])

Time frame:Baseline (week 0), week 68

BMI, change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage change of BMI	95% CI
Semaglutide 2.4 mg	-16.2	—
Placebo	-0.1	—

Treatment difference-16.7595% CI-20.27 – -13.23p<.0001ANCOVA

Primary/protocol endpoint

Change in Body Mass Index (BMI) (Percentage [%])

Time frame:Baseline (week 0), week 68

BMI, change

percent change from baseline, improvement

Secondary/registry result

Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	72.5	—
No	27.5	—
PlaceboYes	17.7	—
No	82.3	—

Secondary/registry result

Change in Body Weight (Kilograms [kg])

Time frame:Baseline (week 0), week 68

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), kg	95% CI
Semaglutide 2.4 mg	-15.7	—
Placebo	2.3	—

Secondary/registry result

Change in Body Weight (%)

Time frame:Baseline (week 0), week 68

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage change of body weight	95% CI
Semaglutide 2.4 mg	-14.8	—
Placebo	2.3	—

Secondary/registry result

Percentage of Participants Achieving >=10% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	61.8	—
No	38.2	—
PlaceboYes	8.1	—
No	91.9	—

Secondary/registry result

Percentage of Participants Achieving >=15% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	53.4	—
No	46.6	—
PlaceboYes	4.8	—
No	95.2	—

Secondary/registry result

Percentage of Participants Achieving >=20% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	37.4	—
No	62.6	—
PlaceboYes	3.2	—
No	96.8	—

Secondary/registry result

Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])

Time frame:Baseline (week 0), week 68

change from baseline, improvement

Posted result

Group	Value (mean), Percentage point of BMI	95% CI
Semaglutide 2.4 mg	-24.9	—
Placebo	-4.5	—

Secondary/registry result

Percentage of Participants Achieving Improvement in Weight Category (Yes/no)

Time frame:At week 68

categorical status, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	71.8	—
No	28.2	—
PlaceboYes	21.0	—
No	79.0	—

Secondary/registry result

Change in BMI (Standard Deviation Score [SDS])

Time frame:Baseline (week 0), week 68

BMI SDS, change

change from baseline, improvement

Posted result

Group	Value (mean), standard deviation score	95% CI
Semaglutide 2.4 mg	-1.1	—
Placebo	-0.1	—

Secondary/registry result

Change in BMI (Kilograms Per Meter Square [kg/m^2])

Time frame:Baseline (week 0), week 68

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kg/m^2	95% CI
Semaglutide 2.4 mg	-5.9	—
Placebo	0.0	—

Secondary/registry result

Change in Waist Circumference

Time frame:Baseline (week 0), week 68

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), cm	95% CI
Semaglutide 2.4 mg	-12.7	—
Placebo	-0.5	—

Secondary/registry result

Percentage of Participants Achieving >=5% Reduction of BMI (Yes/no)

Time frame:At week 68

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
Semaglutide 2.4 mgYes	75.6	—
No	24.4	—
PlaceboYes	22.6	—
No	77.4	—

Secondary/protocol endpoint

Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in Body Weight (Kilograms [kg])

Time frame:Baseline (week 0), week 68

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight (%)

Time frame:Baseline (week 0), week 68

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving >=10% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving >=15% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving >=20% Reduction of Body Weight (Yes/no)

Time frame:At week 68

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])

Time frame:Baseline (week 0), week 68

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving Improvement in Weight Category (Yes/no)

Time frame:At week 68

categorical status, improvement

Secondary/protocol endpoint

Change in BMI (Standard Deviation Score [SDS])

Time frame:Baseline (week 0), week 68

BMI SDS, change

change from baseline, improvement

Secondary/protocol endpoint

Change in BMI (Kilograms Per Meter Square [kg/m^2])

Time frame:Baseline (week 0), week 68

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:Baseline (week 0), week 68

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Percentage of Participants Achieving >=5% Reduction of BMI (Yes/no)

Time frame:At week 68

threshold achievement, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Change in Glycated Haemoglobin (HbA1c) (%)

Time frame:Baseline (week 0), week 68

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage of HbA1c	95% CI
Semaglutide 2.4 mg	-0.4	—
Placebo	-0.1	—

Secondary/registry result

Change in HbA1c (Millimoles Per Mole [mmol/Mol])

Time frame:Baseline (week 0), week 68

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), mmol/mol	95% CI
Semaglutide 2.4 mg	-4.2	—
Placebo	-1.2	—

Secondary/registry result

Change in Fasting Plasma Glucose (Millimoles Per Liter [mmol/L])

Time frame:Baseline (week 0), week 68

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mmol/L	95% CI
Semaglutide 2.4 mg	-0.2	—
Placebo	0.0	—

Secondary/registry result

Change in Fasting Plasma Glucose (Milligrams Per Deciliter [mg/dL])

Time frame:Baseline (week 0), week 68

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mg/dL	95% CI
Semaglutide 2.4 mg	-4.2	—
Placebo	0.0	—

Secondary/registry result

Change in Fasting Insulin (Picomoles Per Liter [Pmol/L]): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting insulin	95% CI
Semaglutide 2.4 mg	0.64	—
Placebo	0.99	—

Secondary/registry result

Change in Fasting Insulin (Milli International Units Per Milliliter [mIU/mL]): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting insulin	95% CI
Semaglutide 2.4 mg	0.64	—
Placebo	0.99	—

Secondary/protocol endpoint

Change in Glycated Haemoglobin (HbA1c) (%)

Time frame:Baseline (week 0), week 68

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c (Millimoles Per Mole [mmol/Mol])

Time frame:Baseline (week 0), week 68

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Fasting Plasma Glucose (Millimoles Per Liter [mmol/L])

Time frame:Baseline (week 0), week 68

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in Fasting Plasma Glucose (Milligrams Per Deciliter [mg/dL])

Time frame:Baseline (week 0), week 68

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in Fasting Insulin (Picomoles Per Liter [Pmol/L]): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, improvement

Secondary/protocol endpoint

Change in Fasting Insulin (Milli International Units Per Milliliter [mIU/mL]): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, improvement

MASH / liver

2 endpoints

Secondary/registry result

Change in Alanine Aminotransferase (ALT): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ALT, change

ratio, improvement

LOINC 1742-6

Posted result

Group	Value (geometric_mean), Ratio of ALT	95% CI
Semaglutide 2.4 mg	0.79	—
Placebo	1.00	—

Secondary/protocol endpoint

Change in Alanine Aminotransferase (ALT): Ratio to Baseline

Time frame:Baseline (week 0), week 68

ALT, change

ratio, improvement

LOINC 1742-6

Cardiometabolic biomarkers

26 endpoints

Secondary/registry result

Change in Systolic Blood Pressure

Time frame:Baseline (week 0), week 68

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), millimeters of mercury (mmHg)	95% CI
Semaglutide 2.4 mg	-3	—
Placebo	-1	—

Secondary/registry result

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), week 68

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), mmHg	95% CI
Semaglutide 2.4 mg	-2	—
Placebo	-1	—

Secondary/registry result

Change in Total Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide 2.4 mg	0.92	—
Placebo	0.98	—

Secondary/registry result

Change in Total Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide 2.4 mg	0.92	—
Placebo	0.98	—

Secondary/registry result

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68:

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide 2.4 mg	1.08	—
Placebo	1.03	—

Secondary/registry result

Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide 2.4 mg	1.08	—
Placebo	1.03	—

Secondary/registry result

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide 2.4 mg	0.91	—
Placebo	0.96	—

Secondary/registry result

Change in LDL Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68:

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide 2.4 mg	0.91	—
Placebo	0.96	—

Secondary/registry result

Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

VLDL, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of VLDL cholesterol	95% CI
Semaglutide 2.4 mg	0.71	—
Placebo	1.03	—

Secondary/registry result

Change in VLDL Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

VLDL, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of VLDL cholesterol	95% CI
Semaglutide 2.4 mg	0.71	—
Placebo	1.03	—

Secondary/registry result

Change in Triglycerides (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide 2.4 mg	0.71	—
Placebo	1.04	—

Secondary/registry result

Change in Triglycerides (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide 2.4 mg	0.71	—
Placebo	1.04	—

Secondary/registry result

Change in Pulse

Time frame:Baseline (week 0), week 68

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), Beats per minute (beats/min)	95% CI
Semaglutide 2.4 mg	0	—
Placebo	-1	—

Secondary/protocol endpoint

Change in Systolic Blood Pressure

Time frame:Baseline (week 0), week 68

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), week 68

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Total Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in Total Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68:

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in LDL Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68:

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

VLDL, change

ratio, improvement

Secondary/protocol endpoint

Change in VLDL Cholesterol (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

VLDL, change

ratio, improvement

Secondary/protocol endpoint

Change in Triglycerides (mmol/L): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Triglycerides, change

ratio, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Triglycerides (mg/dL): Ratio to Baseline

Time frame:Baseline (week 0), week 68

Triglycerides, change

ratio, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Pulse

Time frame:Baseline (week 0), week 68

Heart rate, change

change from baseline, improvement

Safety / tolerability / PK

10 endpoints

Secondary/registry result

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From baseline (week 0) to week 75

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 2.4 mg	792	—
Placebo	328	—

Secondary/registry result

Number of Treatment-emergent Serious Adverse Events (SAEs)

Time frame:From baseline (week 0) to week 75

Serious AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 2.4 mg	17	—
Placebo	7	—

Secondary/registry result

Change in Amylase: Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, descriptive

Posted result

Group	Value (geometric_mean), Ratio of amylase	95% CI
Semaglutide 2.4 mg	1.15	—
Placebo	1.04	—

Secondary/registry result

Change in Lipase: Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, descriptive

Posted result

Group	Value (geometric_mean), Ratio of lipase	95% CI
Semaglutide 2.4 mg	1.39	—
Placebo	1.12	—

Secondary/registry result

Change in Calcitonin: Ratio to Baseline

Time frame:Baseline (week 0), week 68

Thyroid event

ratio, descriptive

Posted result

Group	Value (geometric_mean), Ratio of calcitonin	95% CI
Semaglutide 2.4 mg	1.14	—
Placebo	1.09	—

Secondary/protocol endpoint

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From baseline (week 0) to week 75

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Number of Treatment-emergent Serious Adverse Events (SAEs)

Time frame:From baseline (week 0) to week 75

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Change in Amylase: Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, descriptive

Secondary/protocol endpoint

Change in Lipase: Ratio to Baseline

Time frame:Baseline (week 0), week 68

ratio, descriptive

Secondary/protocol endpoint

Change in Calcitonin: Ratio to Baseline

Time frame:Baseline (week 0), week 68

Thyroid event

ratio, descriptive

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.
Diabetes care2025 Nov 26PMID41296499doi:10.2337/dc25-0824via pubmed nct search
Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.
Obesity (Silver Spring, Md.)2023 Aug (month)PMID37196421doi:10.1002/oby.23808via clinicaltrials gov reference derived + pubmed nct search
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
Journal of comparative effectiveness research2023 Feb (month)PMID36534451doi:10.2217/cer-2022-0187via clinicaltrials gov reference derived + pubmed nct search
Once-Weekly Semaglutide in Adolescents with Obesity.
The New England journal of medicine2022 Dec 15PMID36322838doi:10.1056/NEJMoa2208601via CT.gov reference + pubmed nct search
Progress in pediatric obesity: new and advanced therapies.
Current opinion in pediatrics2022 Aug 1PMID35797460doi:10.1097/MOP.0000000000001150via clinicaltrials gov reference derived + pubmed nct search
Sleep and physical activity patterns in adults and children with Bardet-Biedl syndrome.
Orphanet journal of rare diseases2021 Jun 14PMID34127036doi:10.1186/s13023-021-01911-4via pubmed nct search
Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome.
Pediatric obesity2021 Feb (month)PMID32700463doi:10.1111/ijpo.12703via pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.